Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Synovial 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Melanoma 1 Malignant mesenchymal tumor 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Fibrosarcoma 1 Endometrial Neoplasms 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma, Small Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Pemetrexed 3 Gemcitabine 3 Topotecan 2 Carboplatin 2 vosaroxin 1 vinflunine 1 taxane 1 pembrolizumab 1 lurtotecan 1 liposomal doxorubicin 1 enzalutamide 1 bemiparin 1 apalutamide 1 abiraterone 1 Vinorelbine 1 Temozolomide 1 RRx-001 1 Paclitaxel 1 Nivolumab 1 Irinotecan 1 Ipilimumab 1 Etoposide 1 Docetaxel 1 Cisplatin 1 BI 2536 1 Arsenic Trioxide 1 ARQ 197 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Small Cell × BI 2536 × Clear all

NCT00412880 2022-06-22

BI 2536 Second Line Monotherapy in SCLC

Boehringer Ingelheim

Phase 2 Completed

23 enrolled 10 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡